Suppr超能文献

鉴定药用化合物作为突变异柠檬酸脱氢酶针对软骨肉瘤的潜在抑制剂。

Identification of medicinal compounds as potential inhibitors for mutated isocitrate dehydrogenases against chondrosarcoma.

作者信息

Shah Fahad Hassan, Kim Song Ja

机构信息

Department of Biological Sciences, College of Natural Sciences, Kongju National University, Gongju 32588, Republic of Korea.

出版信息

Saudi J Biol Sci. 2022 Jan;29(1):161-167. doi: 10.1016/j.sjbs.2021.08.077. Epub 2021 Aug 27.

Abstract

Chondrosarcoma is the third most common cartilaginous bone tumour that is insusceptible to radio- and chemotherapy and it is inclined to metastasis. These resistant qualities are facilitated by mutant variants of isocitrate dehydrogenases (IDH) 1-2 enzyme. These mutant enzymes promote oncogenesis of chondrocytes by changing their epigenetic wardrobe leading to tumour formation. Presently, there are lack of drugs available to be exploited as a remedy for this disease. On the other hand, majority of chemotherapeutic drugs induce cytotoxicity in the cancer cells at the cost of harming surrounding healthy cells, jeopardizing human life. The current study is focused on screening various medicinal compounds against IDH1 and IDH2 combined with insilico gene expression, cancer cells cytotoxicity and ADMET (absorption, distribution, metabolism, excretion and toxicity) studies to elucidate the molecular mechanism against chondrosarcoma and also to uncover pharmacokinetic profile of these compounds. Screening of 5000+ compounds filtered two efficacious compounds (Artocarpetin and 5-Galloylquinic acid) capable of establishing hydrogen bond connections with both IDH variants. Other studies showed that these compounds downregulate , , and and gene that reduces chondrogenesis and inflammation, Artocarpetin and 5-galloylquinic acid are TP53 expression enhancer and inhibit MM9 expression that promote immunomodulation and apoptosis in these cancers. These compounds are both active against CHSA8926 and CHSA011 cell line of chondrosarcoma. However, the ADME profile of 5-galloylquinic acid is slightly unsatisfactory based on druglikness and bioavailability score criteria as compared to artocarpetin. Both of these compounds are class-5 chemicals and require high doses to elicit adverse response. Our results suggest that artocarpetin and 5-galloylquinic acid are efficacious drug candidates and could be further exploited to validate these findings .

摘要

软骨肉瘤是第三常见的软骨性骨肿瘤,对放疗和化疗不敏感,且易于转移。异柠檬酸脱氢酶(IDH)1-2酶的突变变体促成了这些抗药特性。这些突变酶通过改变软骨细胞的表观遗传特征促进肿瘤发生,从而导致肿瘤形成。目前,缺乏可用于治疗这种疾病的药物。另一方面,大多数化疗药物在诱导癌细胞产生细胞毒性的同时,也会损害周围的健康细胞,危及生命。当前的研究聚焦于筛选针对IDH1和IDH2的各种药用化合物,并结合计算机基因表达、癌细胞细胞毒性以及ADMET(吸收、分布、代谢、排泄和毒性)研究,以阐明针对软骨肉瘤的分子机制,并揭示这些化合物的药代动力学特征。对5000多种化合物进行筛选后,筛选出了两种有效的化合物(木菠萝素和5-没食子酰奎宁酸),它们能够与两种IDH变体建立氢键连接。其他研究表明,这些化合物下调了 、 、 和 以及 基因,这些基因可减少软骨形成和炎症,木菠萝素和5-没食子酰奎宁酸是TP53表达增强剂,并抑制MM9表达,从而促进这些癌症中的免疫调节和细胞凋亡。这些化合物对软骨肉瘤的CHSA8926和CHSA011细胞系均有活性。然而,根据类药性质和生物利用度评分标准,与木菠萝素相比,5-没食子酰奎宁酸的ADME特征略显不足。这两种化合物均为5类化学品,需要高剂量才能引发不良反应。我们的结果表明,木菠萝素和5-没食子酰奎宁酸是有效的候选药物,可进一步用于验证这些发现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8741/8716869/2615aef66d94/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验